Bacteremia Due to Acinetobacter Genomic Species 10

Shu-Chen Kuo,1 Chang-Phone Fung,1,2 Yi-Tzu Lee,1 Chien-Pei Chen,1 and Te-Li Chen1,2*

Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan,1 and School of Medicine, National Yang-Ming University, Taipei, Taiwan2

Received 21 September 2009/Returned for modification 8 November 2009/Accepted 20 November 2009

Six patients with Acinetobacter genomic species 10 bacteremia were identified. The clinical features of the patients, phenotypic and genotypic identifications, antimicrobial susceptibilities, and genes flanking IS\textit{Abal} of the bacteria were described. The results revealed that this bacterium is a potentially lethal pathogen that can cause health care-associated infections in debilitated patients.

Acinetobacter species that do not belong to the \textit{Acinetobacter calcoaceticus-Acinetobacter baumannii} complex are rarely encountered in clinical practice. Moreover, they cannot be reliably identified by commercially available systems (1, 6, 7). As a result, their clinical significance remains elusive. With the advancement of molecular methods, infections caused by uncommon \textit{Acinetobacter} species, such as \textit{Acinetobacter ursingii}, \textit{Acinetobacter schindleri} (6), and \textit{Acinetobacter septicus} sp. nov. (9), have been described recently.

Although isolates of \textit{Acinetobacter} genomic species 10 (AGS 10), renamed \textit{Acinetobacter berezniae} sp. nov. (13), have previously been identified in clinical samples, they were subjected to studies of identification methods without mention of clinical relevance (10, 15). In this study, we identified AGS 10 isolates from six blood samples. The clinical features of the patients, phenotypic and genotypic identifications, and antimicrobial susceptibilities of the bacteria were described. To our knowledge, this is the largest case series report of AGS 10 infection.

Six of the 47 non-\textit{A. calcoaceticus-A. baumannii} complex strains from a previous study (4) were identified as AGS 10 on the basis of sequence analyses of the 16S-23S rRNA intergenic spacer (ITS) and \textit{recA} gene (2, 10). The bacteria were initially isolated from blood culture by using the BACTEC NR-660 system (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD) and phenotypically identified as \textit{Acinetobacter junii} by the 32GN system (bioMérieux, Marcy l’Etoile, France). The infected patients were men with multiple comorbidities and/or invasive devices (Table 1). Five of the six episodes of bacteremia occurred nosocomially. Patient 2 had just been discharged from our hospital and thus had acquired a health care-associated infection. The patients did not have fever (range, 38.5 to 39.5°C; median, 39.0°C) during bacteremia. All patients had sepsis, while patients 2, 3, and 5 developed septic shock. Blood cultures of all patients yielded only AGS 10. Five patients survived to discharge. One critically ill patient (patient 5) who received inadequate antibiotic therapy succumbed. No other cause of death was identified.

The ITS sequence (793 bp) showed 98 to 99% similarity to the reference strain in GenBank (BCRC 15423, equal to ATCC 17924), while the intraspecies similarity was 97.85 to 99.33%. Neighbor-joining phylogenetic analysis (Fig. 1) utilized sequences of ITS genes from other different \textit{Acinetobacter} species and grouped the clinical isolates and BCRC 15423 into the same cluster. The three most related species were \textit{Acinetobacter} genomic species 11 (BCRC 15424, equal to ATCC 11171), \textit{Acinetobacter} genomic species 14 BJ (CCUG 34435), and \textit{Acinetobacter haemolyticus} (BCRC 14852, equal to ATCC 17906), with similarities of 92.18 to 93.52%, 79.75 to 80.53%, and 79.27 to 80.13%, respectively. Our data demonstrated the specificity of ITS sequencing in identification of AGS 10 in addition to species belonging to the \textit{A. calcoaceticus-A. baumannii} complex (2). The \textit{recA} gene of our strains also showed high sequence similarity (98 to 99%) to the GenBank reference strain (GenBank accession number AF191139) but only 88 to 89% similarity to genomic species 11 (GenBank accession number AF191140). The results revealed that \textit{recA} may be an acceptable and specific tool for identifying AGS 10. Pulsed-field gel electrophoresis (PFGE) (3) revealed no clonal relationship among them (Fig. 2).

It has been assumed that identification of \textit{Acinetobacter} species to the genus level by use of colorimetric Vitek 2 cards (bioMérieux, Marcy l’Etoile, France) is reliable (17). In our study, the colorimetric Vitek 2 cards had identified all clinical strains as \textit{Acinetobacter hofvii} (95 to 99% probability for five isolates and 50.27% for one). The reference strain was identified as \textit{A. hofvii} with lower probability (33.75%). The 32GN system identified the six clinical isolates as \textit{Acinetobacter junii}. Neither the Vitek 2 nor the 32GN system misidentified clinical isolates as members of the \textit{A. calcoaceticus-A. baumannii} complex or another genus.

The \textit{in vitro} susceptibility testing of these clinical isolates and the reference strain was determined by the AST-GN09 card of...
<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yr)/Sex</th>
<th>Underlying condition or diseases</th>
<th>Procedure or invasive device(s)</th>
<th>Treatment</th>
<th>Outcome</th>
<th>Appropriate antimicrobial therapy</th>
<th>Days to resolution of fever</th>
<th>Days to resolution of infection</th>
<th>CRP concn (mg/liter)</th>
<th>WBC count (10^9)/liter</th>
<th>Apache II score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>568 (2002) 79/M</td>
<td>Squamous cell carcinoma of lung postlobectomy, postradiation therapy, hypertension, DM, old CVA, complete AV block post pacemaker</td>
<td>Tracheostomy, ventilator, Foley catheter, CVC, NG</td>
<td>Ciprofloxacin for 14 days</td>
<td>Yes</td>
<td>Survived</td>
<td>1.07</td>
<td>21</td>
<td>0.54</td>
<td>185</td>
<td>16</td>
</tr>
<tr>
<td>2</td>
<td>634 (2002) 78/M</td>
<td>Parkinson’s disease; patient bedridden</td>
<td>Endotracheal tube, ventilator, Foley catheter, CVC, NG</td>
<td>Ampicillin-sulbactam for 2 days followed by piperacillin and amikacin for 14 days</td>
<td>Yes</td>
<td>Survived</td>
<td>0.54</td>
<td>44</td>
<td>1.63</td>
<td>39</td>
<td>21</td>
</tr>
<tr>
<td>3</td>
<td>649 (2002) 81/M</td>
<td>Chronic renal insufficiency, COPD, hypertension, DM, congestive heart failure</td>
<td>Endotracheal tube, ventilator, NG</td>
<td>Ceftazidime for 14 days</td>
<td>Yes</td>
<td>Survived</td>
<td>1.18</td>
<td>55</td>
<td>1.18</td>
<td>55</td>
<td>16</td>
</tr>
<tr>
<td>4</td>
<td>1091 (2005) 38/M</td>
<td>Chronic myeloid leukemia with accelerated blast crisis post nonrelative bone marrow transplant, GVHD under steroid treatment, chronic hepatitis B</td>
<td>Port-A普通 ward/31</td>
<td>Ciprofloxacin for 12 days</td>
<td>Yes</td>
<td>Survived</td>
<td>0.12</td>
<td>0.5</td>
<td>1.18</td>
<td>55</td>
<td>16</td>
</tr>
<tr>
<td>5</td>
<td>1279 (2000) 89/M</td>
<td>CVA; patient bedridden</td>
<td>Tracheostomy, ventilator, Foley catheter, arterial line, CVC, NG</td>
<td>Aztreonam for 13 days</td>
<td>No</td>
<td>Died of disease</td>
<td>1.05</td>
<td>ND</td>
<td>1.05</td>
<td>ND</td>
<td>31</td>
</tr>
<tr>
<td>6</td>
<td>1312 (2000) 82/M</td>
<td>Prior pulmonary tuberculosis, duodenal ulcer post subtotal gastrectomy, hypertension, AVNRT post ablation</td>
<td>Nil</td>
<td>Cefazolin for 15 days plus gentamicin for 9 days</td>
<td>Yes</td>
<td>Survived</td>
<td>1.63</td>
<td>44</td>
<td>21</td>
<td>21</td>
<td>72</td>
</tr>
</tbody>
</table>

**Notes:**

- AV: atrioventricular; AVNRT: atrioventricular nodal reentry tachycardia; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; CVA: cerebrovascular accident; CVC: central venous catheter; DM: diabetes mellitus; GVHD: graft-versus-host disease; ICU: intensive care unit; ND: no data; NG: nasogastric tube; RCU: respiratory intensive care unit; WBC: white blood cell.

- **Case No.**
  - 1: 568 (2002) 79/M
  - 2: 634 (2002) 78/M
  - 3: 649 (2002) 81/M
  - 4: 1091 (2005) 38/M
  - 5: 1279 (2000) 89/M
  - 6: 1312 (2000) 82/M

- **Outcome:**
  - Yes: Survived
  - No: Died of disease

- **Days to resolution of fever:**
  - 1.07
  - 21

- **Days to resolution of infection:**
  - 0.54
  - 44

- **CRP concn (mg/liter):**
  - 0.54
  - 1.63

- **WBC count (10^9)/liter:**
  - 185
  - 39

- **Apache II score:**
  - 1.18
  - 1.63

- **Days to resolution of fever:**
  - 1.07
  - 21

- **Days to resolution of infection:**
  - 0.54
  - 44

- **CRP concn (mg/liter):**
  - 0.54
  - 1.63

- **WBC count (10^9)/liter:**
  - 185
  - 39

**TABLE 1.** Clinical characteristics of patients with Acinetobacter genomic species 10 bacteremia.
the Vitek 2 system or the agar dilution method (colistin). *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as quality control strains. The results were interpreted according to CLSI recommendations (Table 2) (5). The six AGS 10 clinical strains had lower levels of susceptibility to ceftazidime (50%) and ceftriaxone (16.7%) than *A. junii* strains from the same hospital, which exhibited 97.1% and 84.2% susceptibility, respectively, to these two antibiotics (8). Unexpectedly, the reference strain and three clinical strains were resistant to colistin.

Production of beta-lactamases in our clinical isolates and the reference strain was confirmed by a positive colorimetric nitrocefin disk assay (Remel, Lenexa, KS). In spite of resistance to broad-spectrum cephalosporins, five clinical strains and the reference strain lacked detectable extended-spectrum beta-lactamases (ESBLs) and AmpC-type beta-lactamases on the basis of a phenotypic assay (3). Strain 634 expressed AmpC beta-lactamases phenotypically. However, PCR with specific primers failed to detect genes encoding ESBLs and AmpC-type beta-lactamases, including \( \text{bla}_{\text{PER}}, \text{bla}_{\text{SHV}}, \text{bla}_{\text{TEM}}, \text{bla}_{\text{VEB}}, \text{bla}_{\text{CTX-M-1}}, \text{bla}_{\text{CTX-M-2}} \) (TOHO-1).
**TABLE 2. Antimicrobial susceptibility of a reference strain and six clinical isolates of Acinetobacter genomic species 10**

<table>
<thead>
<tr>
<th>Antimicrobial agent(s)</th>
<th>568</th>
<th>634</th>
<th>649</th>
<th>1091</th>
<th>1279</th>
<th>1312</th>
<th>ATCC 17924</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>16</td>
<td>&lt;2</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>8</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Piperacillin</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>&lt;4</td>
<td>&lt;4</td>
<td>&lt;4</td>
<td>&lt;4</td>
<td>&lt;4</td>
<td>&lt;4</td>
<td>&lt;4</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Cefotetan</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>Cefazidime</td>
<td>8</td>
<td>16</td>
<td>4</td>
<td>16</td>
<td>16</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>16</td>
<td>16</td>
<td>8</td>
<td>16</td>
<td>16</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Ceftiraxone</td>
<td>16</td>
<td>16</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>32</td>
<td>&gt;64</td>
<td>16</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
<td>&gt;64</td>
</tr>
<tr>
<td>Imipenem</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Meropenem</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>&lt;0.25</td>
<td>&gt;4</td>
<td>2</td>
<td>&lt;0.25</td>
<td>&gt;4</td>
<td>&lt;0.25</td>
<td>&lt;0.25</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>&lt;0.25</td>
<td>2</td>
<td>1</td>
<td>&lt;0.25</td>
<td>1</td>
<td>&lt;0.25</td>
<td>&lt;0.25</td>
</tr>
<tr>
<td>TMP-SMX*</td>
<td>&lt;20</td>
<td>&lt;20</td>
<td>&gt;320</td>
<td>&lt;20</td>
<td>&gt;320</td>
<td>&lt;20</td>
<td>160</td>
</tr>
<tr>
<td>Colistin</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>16</td>
<td>8</td>
<td>1</td>
<td>4</td>
</tr>
</tbody>
</table>

*TMP-SMX, trimethoprim-sulfamethoxazole.

**FIG. 3.** Comparison of a 2.29-kb HindIII-BamHI fragment from an A. baumannii strain (GenBank accession number AY823412) (A) with a 3.18-kb BamHI fragment from strain 649 (GenBank accession number GQ421466) (B). The region between nucleotides 17 and 637 contained a protein domain resembling the phage-related portal vertex protein of A. baumannii AYE (GenBank accession number Y_P001712545), with 60% identity. ISAbal was located in the region between nucleotides 1861 and 2676. A total of 18 nucleotides downstream of ISAbal initiated an open reading frame matched to sulfonamide resistance gene sulII (GenBank accession number EU360945; 100% similarity), followed by a glmM gene (GenBank accession number EU855788; 99% similarity), which encoded phosphoglucomutase. Arrows indicate the sequences in between two fragments are homologous.

In conclusion, our study revealed that AGS 10 is a potentially lethal pathogen causing health care-associated infections in humans. The identification was achieved by the analysis of ITS and recA gene sequences. Sepsis or even septic shock occurred in vulnerable patients with multiple comorbidities.
and invasive devices. Death may ensue in severely debilitated patients.

This study was supported by grants V98B2-001 from Taipei Veterans General Hospital.

REFERENCES


